AK112 Clinical Trials
15 recruitingDrug
Phase 211Phase 15Phase 33Phase 41
Showing 1–15 of 15 trials
Recruiting
Phase 1Phase 2
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Solid Tumor, Adult
Akeso87 enrolled1 locationNCT05689853
Recruiting
Phase 2
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Hepatocellular Carcinoma (HCC)
Akeso100 enrolled1 locationNCT07052253
Recruiting
Phase 3
AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Akeso416 enrolled1 locationNCT06767527
Recruiting
Phase 3
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Small Cell Lung Cancer
Akeso560 enrolled53 locationsNCT07010263
Recruiting
Phase 3
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Colorectal Adenocarcinoma
Akeso560 enrolled2 locationsNCT06951503
Recruiting
Phase 1Phase 2
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Akeso280 enrolled2 locationsNCT06530251
Recruiting
Phase 2
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Pancreatic Cancer
Akeso160 enrolled2 locationsNCT07114315
Recruiting
Phase 1Phase 2
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Biliary Tract Cancer
Akeso135 enrolled1 locationNCT06938321
Recruiting
Phase 1Phase 2
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Esophageal Squamous Cell CarcinomaNeoadjuvantIvonescimab
Tang-Du Hospital45 enrolled1 locationNCT07385001
Recruiting
Phase 2
A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital30 enrolled1 locationNCT06944106
Recruiting
Phase 1Phase 2
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
Leptomeningeal MetastasisIntrathecal Drug Delivery
Guangzhou Medical University34 enrolled1 locationNCT06809517
Recruiting
Phase 4
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
HCC
The First Affiliated Hospital of Zhengzhou University30 enrolled1 locationNCT06930573
Recruiting
Phase 2
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Recurrent Ovarian Cancer
Akeso172 enrolled1 locationNCT06560112
Recruiting
Phase 2
Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer
Gastric Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School45 enrolled1 locationNCT06791148
Recruiting
Phase 2
A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
Sichuan University28 enrolled1 locationNCT06769295